Jeremy Levin, Ovid CEO (BIO via YouTube)
Ovid shuffles C-suite, lays off staff in wake of PhIII Angelman syndrome fail
Following a Phase III flop and a culling of its pipeline, Ovid Therapeutics is shaking things up again — this time at the C-suite level. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
